Compare AbbVie Inc (ABBV) vs American States Water Company (AWR) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

American States Water (AWR) trades at $83.14, down 1.91% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.66% net margins and consistent dividend growth, though recent earnings show mixed quarterly performance. Recent news highlights AWR's defensive utility characteristics and completion of a $200 million equity offering program.

AWR presents a stable investment case with reliable dividend income and utility sector defensiveness, though valuation appears elevated at 24.24 P/E. Key risks include regulatory rate pressures and execution of capital investments. Analyst sentiment remains cautious with only 20% buy ratings, suggesting limited near-term upside potential despite the company's operational strength.